DIA 2018 Global Annual Meeting
The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.
Oversight in the Era of E6 (R2)
Melissa Bomben, MS
Vice President, Strategic Resourcing
Syneos Health, United States
This session will outline the characteristics that define common outsourcing models and expose their corresponding risk/benefit ratio with regard to sponsor and CRO oversight. Case studies of proven solutions within each model will be presented and linked to recommendations to achieve enhanced oversight in the era of E6 (R2).
Learning Objective : Discuss the risk/benefit ratio with regard to sponsor and CRO oversight in common outsourcing models; Identify methods to implement improved and more efficient approaches to clinical trial oversight.
Cristin MacDonald, PhD
Executive Director, Client Delivery
The Avoca Group, United States
GCP Inspection Lead
Merck & Co., Inc., United States